differences across the specialties. A total of 43% (157 of 368) of total cases involved death of the patient. Among the four specialties, there was a significant (P ¼ .0004) difference in the primary allegation (informed consent, preprocedure negligence, intraprocedural complications, or postprocedural complications) underlying the litigation (Fig). For CTS and VS, there was a predominance of informed consent and preprocedure negligence allegations (70% [7 of 10] and 52% [28 of 54] respectively). Intraprocedural negligence was the most common allegation for IR (59% [23 of 39]), while allegations were more evenly distributed among IC.
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Conclusions: Key issues were identified regarding malpractice litigation involving the specialties that commonly perform endovascular procedures. Despite the increasing number of ICs doing peripheral interventions, a large majority of IC cases were related to coronary treatments. A surprisingly large percentage of VS cases were related to seemingly minor cases. There were significant interspecialty differences in the primary underlying allegations. As the scope of endovascular procedures broadens and deepens, it is important for clinicians to be aware of the legal considerations relevant to their practice. Objectives: Endovascular repair (EVAR) has become the preferred approach to abdominal aortic aneurysm (AAA) due to decreased early morbidity and mortality compared with open repair. However, the ability of EVAR to prevent long-term aneurysm-related mortality (ARM) has been questioned in light of recent trial data. We report our updated long-term EVAR experience in a large multicenter registry to further examine this issue.
Methods: Between 2000 and 2010, 1736 patients with AAA underwent EVAR in a large integrated regional health care system. We extended follow-up in this previously reported cohort through 2015 and identified predictors associated with ARM and need for major reintervention. Primary outcomes were all-cause mortality and ARM. Secondary outcomes were delayed aneurysm rupture, major adverse event (open conversion, major embolic event, graft infection requiring explantation, graft occlusion requiring treatment, aneurysm rupture, graft migration requiring treatment, other), major reintervention (open or endovascular revision), sac growth >5 mm, and type I or III endoleak.
Results: Overall follow-up rate was 97.9%, and median follow-up was 5.5 years (interquartile range, 2.8-7.7). During the study period 958 patients died, of whom 63 experienced ARM (6.6%). Overall freedom from ARM was 96.4%. Life-table analysis at 5 and 10 years showed cumulative survival of 64.4% and 34.6% and freedom from ARM of 96.9% and 94.8%, respectively. Delayed aneurysm rupture was seen in 1.3% (n ¼ 23), with median time to event of 4.1 years (interquartile range, 1.7-7.2). Major adverse event was seen in 12.4%, and major reintervention was performed in 10.3% of patients. Overall freedom from a major adverse event or major reintervention was seen in 84.0%. Sac growth was present in 35.2%. Rates of type I and III endoleak were 7.1% and 2.5%, respectively. Significant predictors of ARM included female sex, age 80-89 years, preoperative AAA size $5.5 cm, urgent EVAR, and any major reintervention. Significant predictors of need for major reintervention included preoperative AAA size $5.5 cm, urgent EVAR, and peripheral vascular disease.
Conclusions: Our results demonstrate favorable long-term freedom from major adverse event or major reintervention after EVAR and extremely low rates of ARM and delayed rupture. This suggests that the higher rates of delayed rupture and ARM seen in other long-term cohorts may not be generalizable to patients who have undergone EVAR with more contemporary devices. Our findings support EVAR as a safe longterm solution for managing patients with AAA and may provide insight into clinical parameters that can be used to stratify patients' post-EVAR surveillance and need for reintervention.
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Methods: Clinical records of 46 patients (25 males and 21 females; mean age, 56.8 years; age range, 32-74 years) with submassive PE who underwent ultrasound-accelerated catheter-directed pulmonary thrombolysis using tissue plasminogen activator (tPA) from 2009 to 2017 were analyzed. All patients experienced clinical symptoms with computed tomography (CT) evidence of pulmonary thrombus burden. Right ventricular dysfunction (RVD) was present in all patients by the echocardiographic finding of a RV-to-left ventricle (RV:LV) ratio >0.9. Treatment outcome, procedural complications, RV pressures, and thrombus clearance were evaluated. Follow-up evaluation include echocardiographic assessment of RV:LV ratio at 1 month, 6 months, and 1 year. Treatment success was defined by the following conditions: restoration of hemodynamic status, improvement of pulmonary hypertension, improvement of RVD, and survival to hospital discharge. Primary safety outcomes were major procedure-related complications and hemorrhagic episodes.
Results: Technical success was achieved in all patients (n ¼ 46 [100%]). Our patients received an average of 27.5 6 2.5 mg of tPA using an ultrasound-accelerated thrombolytic infusion catheter with an average treatment time of 18.6 6 4.6 hours. Clinical success was achieved in 45 patients (98%; 95% confidence interval, 92.4%-99.5%). Significant reduction of mean pulmonary artery pressure occurred after the treatment, which decreased from 53.6 6 16.4 to 32.6 6 18.3 mm Hg (P # .0001). There were two bleeding complications with groin hematoma and flank ecchymosis (n ¼ 2 [4%]), which were treated conservatively. All-cause mortality at 30 days was 0%. No patient developed recurrent PE during follow-up. 
